Literature DB >> 10943680

Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4.

U Pleyer1, E Bertelmann, P Rieck, C Hartmann, H D Volk, T Ritter.   

Abstract

BACKGROUND: Genetic manipulation of the donor cornea ex vivo prior to transplantation may allow modulation of the allogeneic immune response following penetrating keratopasty. In this study we investigated the effect of adenovirus-mediated gene transfer of the Th2 cytokine interleukin-4 (IL-4) to rat corneas in an experimental keratoplasty model.
METHODS: Ex vivo manipulation of Wistar-Furth rat corneas was performed using E1/E3-deleted adenoviral vectors transferring the gene for rat IL-4 (AdrIL-4) under control of the CMV promoter. Following transfection with AdrIL-4 (2 x 10(8) pfu) in DMEM/2% FCS for 3 h, donor corneas were transplanted in MHC class I/II-incompatible Lewis rats. Fifty-two Lewis rats were randomly assigned to receive either nontransfected grafts (n=32), AdrIL-4-transfected grafts (n=8), or syngeneic grafts (n=12).
RESULTS: The rejection rate of AdrIL-4-transfected grafts (85.7%) could not be reduced as compared to controls (62.9%). In addition, the mean survival time of AdrIL-4-transfected grafts (12.6+/-4.5 days) did not differ (P>0.05) from that for untreated transplants (14.1+/-3.8 days).
CONCLUSIONS: Our results indicate that overexpression of IL-4 is not sufficient to reduce the rejection rate of corneal allografts in an experimental keratoplasty model. Further investigations are necessary to identify the reasons for failure and establish more efficient modulatory approaches.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943680     DOI: 10.1007/pl00007896

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  9 in total

Review 1.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

2.  Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases?

Authors:  T Ritter; N Gong; U Pleyer
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

3.  Update on the Management of High-Risk Penetrating Keratoplasty.

Authors:  Sayena Jabbehdari; Alireza Baradaran Rafii; Ghasem Yazdanpanah; Pedram Hamrah; Edward J Holland; Ali R Djalilian
Journal:  Curr Ophthalmol Rep       Date:  2017-02-02

4.  Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival.

Authors:  Svetlana Stanojlovic; Stephan Schlickeiser; Christine Appelt; Katrin Vogt; Isabela Schmitt-Knosalla; Stefanie Haase; Thomas Ritter; Birgit Sawitzki; Uwe Pleyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-24       Impact factor: 3.117

5.  In vitro adenovirus mediated gene transfer to the human cornea.

Authors:  C F Jessup; H M Brereton; D J Coster; K A Williams
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

6.  Effects of a selective glucocorticoid receptor agonist on experimental keratoplasty.

Authors:  Uwe Pleyer; Jun Yang; Sigrid Knapp; Heike Schäcke; Norbert Schmees; Natasa Orlic; Ljijana Otasevic; Maurice De Ruijter; Thomas Ritter; Sigrid Keipert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-04-09       Impact factor: 3.117

7.  Predicting the risk for corneal graft rejection by aqueous humor analysis.

Authors:  Philip Maier; Ulrike Heizmann; Daniel Böhringer; Yvonne Kern; Thomas Reinhard
Journal:  Mol Vis       Date:  2011-04-25       Impact factor: 2.367

Review 8.  Gene therapy in keratoconus.

Authors:  Mahgol Farjadnia; Mohammad Naderan; Mehrdad Mohammadpour
Journal:  Oman J Ophthalmol       Date:  2015 Jan-Apr

Review 9.  Strategies for local gene therapy of corneal allograft rejection.

Authors:  Pho Nguyen; Samuel C Yiu
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.